Inhibition of experimental periodontitis by a topical boron-based antimicrobial.
AN0128 is a boron-containing compound with antibacterial and anti-inflammatory properties. To test its potential effectiveness in treating periodontal disease, we induced experimental periodontitis in the rat by placing ligatures and assessed the impact of AN0128 and positive and negative controls by micro-CT and histologic measurements. The formation of an inflammatory infiltrate was measured in hematoxylin-and-eosin-stained sections. Daily application of AN0128 (1%) compared with controls reduced bone loss by 38 to 44% (P < 0.05), while vehicle alone had no effect (P > 0.05). The reduction in bone loss with AN0128 was similar to that achieved with a NSAID, ketorolac, and Total toothpaste containing triclosan. AN0128 also reduced the level of gingival inflammation 42% compared with the ligature only (P < 0.05), whereas vehicle alone had no effect (P > 0.05). The results indicate that AN0128 significantly reduces the formation of an inflammatory infiltrate and reduces bone loss, measured histologically and by micro-CT.
Luan
Q
Q
Department of Periodontology and Oral Biology, Boston University School of Dental Medicine, Boston, MA 02118, USA.
Desta
T
T
Chehab
L
L
Sanders
V J
VJ
Plattner
J
J
Graves
D T
DT
D016301:Alveolar Bone Loss / Q000473:pathology / Q000517:prevention & control; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001880:Boranes / Q000627:therapeutic use*; D004396:Coloring Agents; D045424:Complex Mixtures / Q000627:therapeutic use; D003802:Dentifrices / Q000627:therapeutic use; D005026:Ethylene Glycols; D005456:Fluorescent Dyes; D005459:Fluorides / Q000627:therapeutic use; D005891:Gingivitis / Q000473:pathology / Q000517:prevention & control; D020910:Ketorolac / Q000627:therapeutic use; D008297:Male; D010518:Periodontitis / Q000473:pathology / Q000517:prevention & control*; D014677:Pharmaceutical Vehicles; D011725:Pyridines / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012824:Silicic Acid; D014057:Tomography, X-Ray Computed / Q000379:methods; D014100:Toothpastes; D014260:Triclosan / Q000627:therapeutic use
C515885:3-hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane; D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001880:Boranes; D004396:Coloring Agents; D045424:Complex Mixtures; D003802:Dentifrices; D005026:Ethylene Glycols; D005456:Fluorescent Dyes; D014677:Pharmaceutical Vehicles; D011725:Pyridines; D014100:Toothpastes; C546060:hydrated silica gel-based toothpaste; D012824:Silicic Acid; D014260:Triclosan; C010111:carbitol; D005459:Fluorides; D020910:Ketorolac